|
Coogan et al. [26]
|
207
|
5,833a
|
Hospital based
|
>4 days/week for >3 months. Continuing use during 1 year of lag time
|
Personal Interview
|
NSAIDs (7%)
|
0.8
|
0.5–1.4
|
|
Farrow et al. [30]
|
277
|
687a
|
Population based
|
>1 tablet/week during >6 months. 1 year lag time
|
Personal Interview
|
Aspirin (31%)
|
0.48†
|
0.32–0.70
|
| |
279
| | | | |
NA-NSAIDs (13%)
|
0.81†
|
0.51–1.30
|
|
Langman et al. [36]
|
550
|
1,650a
|
Population based
|
>7 prescriptions during months 13–36 before index date
|
Automated Database
|
NSAIDs (8%)
|
0.64
|
0.41–0.98
|
|
Garidou et al. [32]
|
56
|
200a
|
Hospital based
|
Chronic intake
|
Personal Interview
|
NSAIDs (14%)
|
0.52†
|
0.17–1.62
|
|
Suleiman et al. [59]
|
56
|
56a
|
Population based
|
Ever use for >1 year
|
Medical records
|
NSAIDs (38%)
|
0.16
|
0.03–0.93
|
|
Cheng et al. [60]
|
74
|
74a
|
Population based
|
Ever daily use for >1 month
|
Personal Interview
|
Aspirin (21%)
|
0.67
|
0.27–1.63
|
|
Funkhouser et al.31
|
15
|
13,179b
|
Cohort
|
Use 30 days before baseline (ocasional)
|
Personal Interview
|
Aspirin (51%)
|
0.10
|
0.01–0.76
|
|
Thun et al. [46]
|
157
|
635,031b
|
Cohort
|
More than 16 times per month for at least one year
|
Mailed questionnaire
|
Aspirin (11%)
|
0.59
|
0.34–1.03
|
